In early-onset Alzheimer’s disease (EOAD) and late-onset Alzheimer’s disease (LOAD), APOE genotype differentially affect Papez circuit structures as well as cognitive performance.
Why this matters?
The structural, cognitive and neuropsychiatric differences between EOAD (age at symptom onset <65 years) and LOAD (age at symptom onset ≥65 years) have been recognized. However, previous studies often lacked information on biomarker confirmation and/or APOE genotype.
Future research on AD and clinical trial designs should take APOE genotype as well as the age of symptom onset into consideration.